Drugs / TGRX-1942
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06484816 | Jul 2024 → Feb 2027 expected | hematopoietic and lymphoid cell neoplasm, non-small cell lung carcinoma | Shenzhen TargetRx Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGRX-1942 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06484816 ↗ |
| Route | Oral | “TGRX-1942 will be given orally to patient once a day” NCT06484816 ↗ |